Does tocilizumab have an effect on the clinical outcomes in COVID-19 patients? A meta-analysis of randomized control trials

References

• Wu A, et al.Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in ChinaCell Host Microbe2020273325328 1:CAS:528:DC%2BB3cXivVeiu7s%3D 32035028 7154514 10.1016/j.chom.2020.02.001
   PubMed Web of Science ®Google Scholar
• Organization, W.H., World Health Organization Coronavirus Disease (COVID-19): Weekly Epidemiological Update. 2021.
   Google Scholar
• Phelan AL, Katz R, Gostin LOThe novel coronavirus originating in Wuhan, China: challenges for global health governanceJAMA20203238709710 1:CAS:528:DC%2BB3cXpvFOjtLw%3D 31999307 10.1001/jama.2020.1097
   PubMed Web of Science ®Google Scholar
• Zhang C, et al.Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortalityInt J Antimicrob Agents2020555 1:CAS:528:DC%2BB3cXmsFOjtbc%3D 32234467 7118634 10.1016/j.ijantimicag.2020.105954
   PubMed Web of Science ®Google Scholar
• Coperchini F, et al.The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor systemCytokine Growth Factor Rev2020532532 1:CAS:528:DC%2BB3cXhtVaqtr7M 32446778 7211650 10.1016/j.cytogfr.2020.05.003
   PubMed Web of Science ®Google Scholar
• Tanaka T, Narazaki M, Kishimoto TIL-6 in inflammation, immunity, and diseaseCold Spring Harb Perspect Biol2014610 25190079 4176007 10.1101/cshperspect.a016295
   PubMed Web of Science ®Google Scholar
• Laguna-Goya, R., et al., IL-6–based mortality risk model for hospitalized patients with COVID-19. Journal of Allergy and Clinical Immunology, 2020. 146(4): p. 799–807. e9.
   Google Scholar
• Singh JA, Beg S, Lopez-Olivo MATocilizumab for rheumatoid arthritis: a Cochrane systematic reviewJ Rheumatol20113811020 20952462 3882031 10.3899/jrheum.100717
   PubMed Web of Science ®Google Scholar
• Rubbert-Roth A, et al.A review of recent advances using tocilizumab in the treatment of rheumatic diseasesRheumatology and therapy2018512142 29502236 5935615 10.1007/s40744-018-0102-x
   PubMed Web of Science ®Google Scholar
• Lee DW, et al.Current concepts in the diagnosis and management of cytokine release syndromeBlood, The Journal of the American Society of Hematology20141242188195 1:CAS:528:DC%2BC2cXht1WktbrM
   Google Scholar
• Tleyjeh IM, et al.Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first updateClin Microbiol Infect202127810761082 1:CAS:528:DC%2BB3MXhtFahsL%2FE 33915284 8076756 10.1016/j.cmi.2021.04.019
   PubMed Web of Science ®Google Scholar
• Guaraldi G, et al.Tocilizumab in patients with severe COVID-19: a retrospective cohort studyThe Lancet Rheumatology202028e474e484 32835257 7314456 10.1016/S2665-9913(20)30173-9
   PubMedGoogle Scholar
• Charan J, et al.Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO databaseExpert Opin Drug Saf202120911251136 1:CAS:528:DC%2BB3MXhsVenu7nM 34162299 10.1080/14740338.2021.1946513
   PubMed Web of Science ®Google Scholar
• Tleyjeh IM, et al.Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysisClin Microbiol Infect2021272215227 1:CAS:528:DC%2BB3cXisVOltr7K 10.1016/j.cmi.2020.10.036
   PubMed Web of Science ®Google Scholar
• Aziz M, et al.Efficacy of tocilizumab in COVID-19: a systematic review and meta-analysisJ Med Virol202193316201630 1:CAS:528:DC%2BB3cXhvFWmu7bP 32918755 10.1002/jmv.26509
   PubMed Web of Science ®Google Scholar
• Piscoya A, et al.Efficacy and harms of tocilizumab for the treatment of COVID-19 patients: A systematic review and meta-analysisPLoS ONE2022176 1:CAS:528:DC%2BB38XhsV2isb7I 35657993 9165853 10.1371/journal.pone.0269368
   PubMed Web of Science ®Google Scholar
• Della-Torre E, et al.Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort studyAnn Rheum Dis2020791012771285 1:CAS:528:DC%2BB3cXitFaks73I 32620597 10.1136/annrheumdis-2020-218122
   PubMed Web of Science ®Google Scholar
• Page MJ, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviewsSyst Rev2021101111 10.1186/s13643-021-01626-4
   PubMed Web of Science ®Google Scholar
• Moher, D., et al., The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. 2001, Elsevier.
   Google Scholar
• Schulz KF, Altman DG, Moher DCONSORT 2010 statement: updated guidelines for reporting parallel group randomised trialsBMC Med20108118 20334633 2860339 10.1186/1741-7015-8-18
   PubMed Web of Science ®Google Scholar
• Higgins JP, et al.The Cochrane Collaboration’s tool for assessing risk of bias in randomised trialsBMJ2011343 22008217 3196245 10.1136/bmj.d5928
   PubMedGoogle Scholar
• Veiga, V.C., et al., Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. bmj, 2021. 372.
   Google Scholar
• Rosas, I.O., et al., Tocilizumab in hospitalized patients with COVID-19 pneumonia. MedRxiv, 2020.
   Google Scholar
• Wang, D., et al., Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Front Med 2021.[Epub ahead of print]. PUBMED.
   Google Scholar
• Capra R, et al.Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumoniaEur J Intern Med2020763135 1:CAS:528:DC%2BB3cXpt12gtb4%3D 32405160 7219361 10.1016/j.ejim.2020.05.009
   PubMed Web of Science ®Google Scholar
• Rashad A, et al.Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or TocilizumabSci Rep202111117 10.1038/s41598-021-88086-x
   PubMed Web of Science ®Google Scholar
• Hermine O, et al.Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trialJAMA Intern Med202118113240 1:CAS:528:DC%2BB3MXitl2gsrs%3D 10.1001/jamainternmed.2020.6820
   PubMed Web of Science ®Google Scholar
• Soin AS, et al.Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trialLancet Respir Med202195511521 1:CAS:528:DC%2BB3MXmtFKjsr4%3D 33676589 8078880 10.1016/S2213-2600(21)00081-3
   PubMed Web of Science ®Google Scholar
• Perrone, F., et al., Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. Journal of translational medicine, 2020. 18(1): p. 1–11.
   Google Scholar
• Rocco, P.R., et al., Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial. European Respiratory Journal, 2021. 58(1).
   Google Scholar
• Hamed DM, et al.Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support: A prospective comparisonJ Infect Public Health2021148985989 34153729 8191304 10.1016/j.jiph.2021.06.003
   PubMed Web of Science ®Google Scholar
• Zhao H, et al.Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample sizeBiomed Pharmacother2021133 1:CAS:528:DC%2BB3cXisFent77E 33378989 10.1016/j.biopha.2020.110825
   PubMed Web of Science ®Google Scholar
• Strohbehn GW, et al.COVIDOSE: a phase II clinical trial of low-dose tocilizumab in the treatment of noncritical COVID-19 pneumoniaClin Pharmacol Ther20211093688696 1:CAS:528:DC%2BB3MXltFKntLY%3D 33210302 10.1002/cpt.2117
   PubMed Web of Science ®Google Scholar
• Baker, E.H., et al., Insights from compassionate use of tocilizumab for COVID‐19 to inform appropriate design of randomised controlled trials. British Journal of Clinical Pharmacology, 2021.
   Google Scholar
• McAuley, D. and R.-C.W. Committee, Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2021.
   Google Scholar
• Dastan F, et al.Promising effects of tocilizumab in COVID-19: a non-controlled, prospective clinical trialInt Immunopharmacol202088 1:CAS:528:DC%2BB3cXhslygsb%2FE 32889241 7402206 10.1016/j.intimp.2020.106869
   PubMed Web of Science ®Google Scholar
• Pomponio G, et al.Tocilizumab in COVID-19 interstitial pneumoniaJ Intern Med20212895738746 1:CAS:528:DC%2BB3MXptl2ktb8%3D 33511686 8013903 10.1111/joim.13231
   PubMed Web of Science ®Google Scholar
• Salama, C. and S.V. Mohan, Tocilizumab in patients hospitalized with Covid-19 pneumonia. Reply. The New England journal of medicine, 2021.
   Google Scholar
• Khiali S, Khani E, Entezari-Maleki TA comprehensive review of tocilizumab in COVID-19 acute respiratory distress syndromeJ Clin Pharmacol202060911311146 1:CAS:528:DC%2BB3cXhsV2msbjO 32557541 7323169 10.1002/jcph.1693
   PubMed Web of Science ®Google Scholar
• Oldfield V, Dhillon S, Plosker GLTocilizumabDrugs2009695609632 1:CAS:528:DC%2BD1MXnsFOiu7g%3D 19368420 10.2165/00003495-200969050-00007
   PubMed Web of Science ®Google Scholar
• Toniati P, et al.Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, ItalyAutoimmun Rev2020197 1:CAS:528:DC%2BB3cXpvFGmt7w%3D 32376398 7252115 10.1016/j.autrev.2020.102568
   PubMed Web of Science ®Google Scholar
• Anka AU, et al.Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and managementScand J Immunol2021934 1:CAS:528:DC%2BB3MXnt1art7w%3D 33190302 10.1111/sji.12998
   PubMed Web of Science ®Google Scholar
• Li G, et al.Coronavirus infections and immune responsesJ Med Virol2020924424432 1:CAS:528:DC%2BB3cXntVKntr4%3D 31981224 7166547 10.1002/jmv.25685
   PubMed Web of Science ®Google Scholar
• Ivashkiv LB, Donlin LTRegulation of type I interferon responsesNat Rev Immunol20141413649 1:CAS:528:DC%2BC3sXhvFOltLvJ 24362405 4084561 10.1038/nri3581
   PubMed Web of Science ®Google Scholar
• Khosroshahi LM, et al.Immunology, immunopathogenesis and immunotherapeutics of COVID-19; an overviewInt Immunopharmacol202193 10.1016/j.intimp.2020.107364
   Web of Science ®Google Scholar
• Hu B, Huang S, Yin LThe cytokine storm and COVID-19J Med Virol2021931250256 1:CAS:528:DC%2BB3cXhvFCrurzN 32592501 10.1002/jmv.26232
   PubMed Web of Science ®Google Scholar
• Coomes EA, Haghbayan HInterleukin-6 in COVID-19: a systematic review and meta-analysisRev Med Virol202030619 1:CAS:528:DC%2BB3cXisVOmu73F 32845568 10.1002/rmv.2141
   PubMed Web of Science ®Google Scholar
• Gaestel, M., A.R. Nebreda, and M.B. Yaffe, Cytokine Storm. 2021.
   Google Scholar
• Tan M, et al.Immunopathological characteristics of coronavirus disease 2019 cases in GuangzhouChina Immunology20201603261268 1:CAS:528:DC%2BB3cXhtlaitb7P 32460357 10.1111/imm.13223
   PubMed Web of Science ®Google Scholar
• Shimabukuro-Vornhagen A, et al.Cytokine release syndromeJ Immunother Cancer201861114 10.1186/s40425-018-0343-9
   PubMedGoogle Scholar
• Thompson BT, Chambers RC, Liu KDAcute respiratory distress syndromeN Engl J Med20173776562572 1:CAS:528:DC%2BC2sXhtlyksrbO 28792873 10.1056/NEJMra1608077
   PubMed Web of Science ®Google Scholar
• Matthay MA, et al.Acute respiratory distress syndromeNat Rev Dis Primers201951122 10.1038/s41572-019-0069-0
   PubMed Web of Science ®Google Scholar
• Snow TAC, et al.Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trialsIntensive Care Med2021476641652 1:CAS:528:DC%2BB3MXhtFGlsL3E 34019122 8139226 10.1007/s00134-021-06416-z
   PubMed Web of Science ®Google Scholar
• Mahroum N, et al.Systematic review and meta-analysis of tocilizumab therapy versus standard of care in over 15,000 COVID-19 pneumonia patients during the first eight months of the pandemicInt J Environ Res Public Health202118179149 1:CAS:528:DC%2BB3MXitFGnsrrE 34501738 8431489 10.3390/ijerph18179149
   PubMed Web of Science ®Google Scholar
• Kotak, S., et al., Use of tocilizumab in COVID-19: a systematic review and meta-analysis of current evidence. Cureus, 2020. 12(10).
   Google Scholar